Association of Optimal Implementation of Sodium-Glucose Cotransporter 2 Inhibitor Therapy With Outcome for Patients With Heart Failure

Authors:

Abstract
Sodium-glucose cotransporter 2 inhibitor (SGLT2-i) therapy was initially directed toward the management of type 2 diabetes. The first cardiovascular clinical outcome trial of SGLT2-i therapy, the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME), demonstrated an unexpected and substantial reduction in all-cause mortality, cardiovascular death, and heart failure (HF) hospitalizations among patients with type 2 diabetes.1 Significant reductions in HF hospitalizations were also demonstrated with the SGLT2-i canagliflozin in the Canagliflozin Cardiovascular Assessment Study2 and with dapagliflozin in the Dapagliflozin Effect on Cardiovascular Events trial,3 thus confirming the EMPA-REG OUTCOME findings. Sodium-glucose cotransporter 2 inhibitors are now established as among the most effective therapies to prevent HF in patients with type 2 diabetes.4